论文部分内容阅读
目的:测定经皮腔内冠状动脉介入术(PCI)后C-反应蛋白(CRP)的水平并评价阿托伐他汀对其影响。方法:连续选择因冠状动脉狭窄性病变行PCI的冠心病患者60例,随机分为治疗组和对照组,治疗组在对照组治疗的基础上给予阿托伐他汀20mg,qd,术前及术后2d和3周分别测外周动脉血清CRP。结果:术前、术后2d及术后3周,治疗组CRP水平分别为(9.03±0.59)、(23.5±0.71)及(12.8±0.47)mg/L,对照组则分别为(8.8±0.62)、(21.2±0.56)及(19.6±0.53)mg/L,两组术后3周比较,差异有统计学意义(P<0.01);术前、术后2d及术后3周治疗组CK-MB分别为(11.9±3.3)、(14.6±3.2)、(16.0±2.8)IU/L,对照组为(12.1±3.4)、(14.3±2.6)、(15.6±3.0)IU/L,两组术后CK-MB均无升高,两组术前、术后相比较,均P>0.05。结论:PCI后血清CRP水平升高,阿托伐他汀可明显控制血浆炎症因子,有利于动脉粥样硬化斑块的稳定。
Objective: To determine the level of C-reactive protein (CRP) after percutaneous transluminal coronary angioplasty (PCI) and evaluate the effect of atorvastatin on it. Methods: Sixty consecutive coronary artery disease patients with coronary artery stenosis were randomly divided into treatment group and control group. The treatment group was given atorvastatin 20 mg, qd, preoperative and postoperative Peripheral arterial serum CRP was measured 2 days and 3 weeks later. Results: The levels of CRP in the treatment group were (9.03 ± 0.59), (23.5 ± 0.71) and (12.8 ± 0.47) mg / L preoperatively, 2 days and 3 weeks after operation, respectively, while those in the control group were (8.8 ± 0.62 ), (21.2 ± 0.56) and (19.6 ± 0.53) mg / L, respectively. The difference between the two groups was statistically significant at 3 weeks after operation (P <0.01) -MB were (11.9 ± 3.3), (14.6 ± 3.2) and (16.0 ± 2.8) IU / L in the control group and (12.1 ± 3.4) and (14.3 ± 2.6) and (15.6 ± 3.0) IU / There was no increase in CK-MB after operation in both groups, P> 0.05 before and after operation. Conclusion: Serum CRP levels increased after PCI, atorvastatin can significantly control the plasma inflammatory cytokines, is conducive to the stability of atherosclerotic plaque.